Scarica l'app Stockscreener
72.31
5.56%
3.81
Pre-mercato:
72.39
0.08
+0.11%
Precedente Chiudi:
$68.50
Aprire:
$70.3
Volume 24 ore:
1.36M
Relative Volume:
1.42
Capitalizzazione di mercato:
$4.94B
Reddito:
-
Utile/perdita netta:
$-146.66M
Rapporto P/E:
-26.26
EPS:
-2.7541
Flusso di cassa netto:
$-133.21M
1 W Prestazione:
+2.00%
1M Prestazione:
+11.45%
6M Prestazione:
+94.75%
1 anno Prestazione:
+138.10%
Intervallo 1D:
$69.34
$74.09
Intervallo di 1 settimana:
$66.00
$74.09
Portata 52W:
$26.20
$84.56
Apogee Therapeutics Inc Stock (APGE) Company Profile
Nome
Apogee Therapeutics Inc
Settore
Industria
Telefono
650-394-5230
Indirizzo
221 CRESCENT ST., WALTHAM
Compare APGE vs VRTX, REGN, ARGX, ALNY, ONC
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
APGE
Apogee Therapeutics Inc
|
72.31 | 4.68B | 0 | -146.66M | -133.21M | -2.7541 |
|
VRTX
Vertex Pharmaceuticals Inc
|
477.89 | 120.48B | 12.07B | 3.95B | 3.19B | 15.33 |
|
REGN
Regeneron Pharmaceuticals Inc
|
787.50 | 81.05B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
749.56 | 46.33B | 4.16B | 1.29B | 734.26M | 19.59 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
327.30 | 42.26B | 3.71B | 313.75M | 465.38M | 2.2571 |
|
ONC
Beone Medicines Ltd Adr
|
299.02 | 32.87B | 5.36B | 287.73M | 924.18M | 2.5229 |
Apogee Therapeutics Inc Stock (APGE) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2026-01-22 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| 2026-01-07 | Iniziato | Wolfe Research | Peer Perform |
| 2025-12-17 | Iniziato | Stephens | Overweight |
| 2025-12-10 | Iniziato | Deutsche Bank | Buy |
| 2025-11-03 | Iniziato | Craig Hallum | Buy |
| 2025-10-21 | Iniziato | Mizuho | Outperform |
| 2025-09-25 | Iniziato | RBC Capital Mkts | Outperform |
| 2025-07-07 | Reiterato | BTIG Research | Buy |
| 2025-03-13 | Iniziato | Citigroup | Buy |
| 2024-11-25 | Iniziato | Canaccord Genuity | Buy |
| 2024-05-10 | Iniziato | BofA Securities | Buy |
| 2023-12-20 | Iniziato | BTIG Research | Buy |
| 2023-08-08 | Iniziato | Guggenheim | Buy |
| 2023-08-08 | Iniziato | Jefferies | Buy |
| 2023-08-08 | Iniziato | Stifel | Buy |
| 2023-08-08 | Iniziato | TD Cowen | Outperform |
| 2023-08-08 | Iniziato | Wedbush | Outperform |
Mostra tutto
Apogee Therapeutics Inc Borsa (APGE) Ultime notizie
Rafferty Asset Management LLC Acquires 23,585 Shares of Apogee Therapeutics Inc. $APGE - MarketBeat
Apogee Therapeutics (APGE) Gets a Buy from Mizuho Securities - The Globe and Mail
Apogee Therapeutics Teases 52-Week Zumi Durability Data, Phase III Path at TD Cowen Conference - Yahoo Finance
Is Rising R&D Spend And New Equity Shelf Altering The Investment Case For Apogee Therapeutics (APGE)? - Yahoo Finance
Apogee Therapeutics (APGE) Stock Analysis: Exploring a 47.76% Potential Upside in the Biotech Sector - DirectorsTalk Interviews
Apogee Therapeutics (NASDAQ:APGE) Price Target Raised to $95.00 - MarketBeat
RBC Lowers Price Target on Apogee Therapeutics to $82 From $83, Keeps Sector Perform, Speculative Risk - marketscreener.com
Apogee Therapeutics Stock: Clinical-Stage Risks, Unproven Pipeline, and Uncertain Path to Profitability - TipRanks
Decoding Apogee Therapeutics Inc (APGE): A Strategic SWOT Insigh - GuruFocus
RBC Capital lowers Apogee Therapeutics stock price target on dosing outlook By Investing.com - Investing.com Australia
RBC Capital lowers Apogee Therapeutics stock price target on dosing outlook - Investing.com
Key facts: Apogee Therapeutics posts $285.6M loss; plans Phase 3 trial - TradingView
APGE Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
Apogee Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2025 - marketscreener.com
Apogee Therapeutics Inc reports results for the quarter ended December 31Earnings Summary - TradingView
Wedbush Adjusts Price Target on Apogee Therapeutics to $95 From $90, Maintains Outperform Rating - marketscreener.com
APOGEE THERAPEUTICS ($APGE) Releases Q4 2025 Earnings - Quiver Quantitative
Apogee Therapeutics (NASDAQ:APGE) Releases Earnings Results, Beats Expectations By $0.02 EPS - MarketBeat
APGE: Strong pipeline progress and robust cash reserves position for key data and trial milestones in 2026 - TradingView
Apogee Therapeutics 2025 10-K: $0 Revenue; EPS $(4.22) - TradingView
Apogee Therapeutics (NASDAQ: APGE) advances long-acting AD biologics - Stock Titan
Apogee biotech with $902.9M cash eyes possible 2029 atopic dermatitis drug - Stock Titan
Precision Trading with Apogee Therapeutics Inc. (APGE) Risk Zones - Stock Traders Daily
JPMorgan Chase & Co. Purchases 417,161 Shares of Apogee Therapeutics Inc. $APGE - MarketBeat
APGE SEC FilingsApogee Therapeutics Inc 10-K, 10-Q, 8-K Forms - Stock Titan
Apogee Therapeutics Stock Up 100% as Fund Lifts Stake to $28 Million - AOL.com
Apogee Therapeutics Stock Up 100% as Fund Lifts Stake to $28 Million - The Motley Fool
Apogee Therapeutics, Inc. (APGE) Stock Analysis: A Promising Biotech with Nearly 50% Upside Potential - DirectorsTalk Interviews
Apogee Therapeutics to Participate in Upcoming March Conferences - The Manila Times
Biotech roadshow: Apogee Therapeutics plans three March conferences - Stock Titan
Apogee Therapeutics (APGE) Expected to Announce Earnings on Monday - Defense World
Apogee Shares Up Nearly 100% in 12 Months, and This $62 Million Buy Signals Ongoing Conviction - Yahoo Finance
Aberdeen Group plc Takes Position in Apogee Therapeutics Inc. $APGE - MarketBeat
RBC Capital Initiates Coverage of Apogee Therapeutics (APGE) With an Outperform Rating - MSN
Apogee Therapeutics Inc. (NASDAQ:APGE) Given Average Rating of "Moderate Buy" by Brokerages - MarketBeat
What is Apogee Therapeutics Inc. s 5 year growth outlookJuly 2025 Rallies & Stock Market Timing Techniques - mfd.ru
End of Apogee (APGE) drug collaboration leads to revised analyst expectations - MSN
Apogee Therapeutics Rings the Closing Bell - Nasdaq
End of Apogee (APGE) Drug Collaboration Leads to Revised Analyst Expectations - Finviz
Technical Reactions to APGE Trends in Macro Strategies - Stock Traders Daily
Does Apogee Therapeutics' (APGE) Rebound After Sanofi Amlitelimab Jitters Clarify Its Competitive Position? - Sahm
Apogee Therapeutics (APGE) Stock Analysis: A Biotech Gem With 53.86% Potential Upside - DirectorsTalk Interviews
Is Apogee Therapeutics (APGE) Now Defined by Its IL-13/OX40L Positioning Against Sanofi? - Yahoo Finance
Here is Why Apogee Therapeutics (APGE) Appears Attractive - Yahoo Finance
CEO Moves: What is Apogee Therapeutics Inc. s 5 year growth outlook2025 Market WrapUp & Weekly Top Gainers Trade List - mfd.ru
Apogee Stock Jumps 87% in One Year as This Biotech Fund Lifts Stake to $93 Million - Yahoo Finance
Michael Thomas Henderson Sells 20,000 Shares of Apogee Therapeutics (NASDAQ:APGE) Stock - MarketBeat
CEO Michael Henderson Sells 20,000 Shares of Apogee Therapeutics Inc - GuruFocus
Apogee Therapeutics CEO Sells 20,000 Shares - TradingView
What’s the beta of Apogee Therapeutics Inc. stockTrade Volume Report & Technical Pattern Alert System - mfd.ru
Apogee Therapeutics touts quarterly-to-biannual AD dosing shift, expands asthma ambitions at conference - MarketBeat
Apogee Therapeutics Inc Azioni (APGE) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.11%
6.00%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):